CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Stifel Financial Corp

Stifel Financial Corp increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 7.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 43,128 shares of the company’s stock after purchasing an additional 2,891 shares during the quarter. Stifel Financial Corp owned 0.05% of CRISPR Therapeutics worth $1,698,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CRSP. Tower Research Capital LLC TRC increased its position in shares of CRISPR Therapeutics by 499.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,453 shares of the company’s stock worth $215,000 after acquiring an additional 4,544 shares in the last quarter. Curi RMB Capital LLC increased its holdings in CRISPR Therapeutics by 5.0% in the 4th quarter. Curi RMB Capital LLC now owns 49,061 shares of the company’s stock valued at $1,931,000 after purchasing an additional 2,346 shares in the last quarter. Dimensional Fund Advisors LP raised its position in CRISPR Therapeutics by 14.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 947,301 shares of the company’s stock valued at $37,283,000 after purchasing an additional 122,695 shares during the period. Freedom Investment Management Inc. boosted its position in shares of CRISPR Therapeutics by 22.7% in the fourth quarter. Freedom Investment Management Inc. now owns 10,017 shares of the company’s stock worth $394,000 after buying an additional 1,856 shares during the period. Finally, Capital International Ltd. CA grew its stake in shares of CRISPR Therapeutics by 2.2% in the fourth quarter. Capital International Ltd. CA now owns 128,380 shares of the company’s stock valued at $5,053,000 after buying an additional 2,776 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, COO Julianne Bruno sold 1,198 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the transaction, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. This represents a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $120,897.00. Following the sale, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. This trade represents a 3.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock worth $1,608,243 in the last 90 days. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $33.21 on Wednesday. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $67.88. The firm’s 50-day moving average is $38.62 and its 200-day moving average is $43.00. The company has a market cap of $2.87 billion, a P/E ratio of -7.60 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. CRISPR Therapeutics’s revenue for the quarter was up 71.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.43) earnings per share. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Ratings Changes

CRSP has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, April 9th. Bank of America lowered their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Truist Financial boosted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. The Goldman Sachs Group lowered their target price on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Finally, TD Cowen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $73.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.